| Brine shrimp: a convenient general bioassay for active plant constituents BN Meyer, NR Ferrigni, JE Putnam, LB Jacobsen, DEJ Nichols, ... Planta medica 45 (05), 31-34, 1982 | 7370 | 1982 |
| Hallucinogens DE Nichols Pharmacology & therapeutics 101 (2), 131-181, 2004 | 1702 | 2004 |
| Psychedelics DE Nichols Pharmacological reviews 68 (2), 264-355, 2016 | 1692 | 2016 |
| Functional selectivity and classical concepts of quantitative pharmacology JD Urban, WP Clarke, M Von Zastrow, DE Nichols, B Kobilka, H Weinstein, ... Journal of Pharmacology and Experimental Therapeutics 320 (1), 1-13, 2007 | 1324 | 2007 |
| Serotonin receptors DE Nichols, CD Nichols Chemical reviews 108 (5), 1614-1641, 2008 | 1243 | 2008 |
| Neural correlates of the LSD experience revealed by multimodal neuroimaging RL Carhart-Harris, S Muthukumaraswamy, L Roseman, M Kaelen, ... Proceedings of the National Academy of Sciences 113 (17), 4853-4858, 2016 | 923 | 2016 |
| Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens DE Nichols Journal of psychoactive drugs 18 (4), 305-313, 1986 | 681 | 1986 |
| Crystal structure of an LSD-bound human serotonin receptor D Wacker, S Wang, JD McCorvy, RM Betz, AJ Venkatakrishnan, A Levit, ... Cell 168 (3), 377-389. e12, 2017 | 480 | 2017 |
| Effects of Schedule I drug laws on neuroscience research and treatment innovation DJ Nutt, LA King, DE Nichols Nature Reviews Neuroscience 14 (8), 577-585, 2013 | 405 | 2013 |
| Effects of enantiomers of MDA, MDMA and related analogues on [3H] serotonin and [3H] dopamine release from superfused rat brain slices MP Johnson, AJ Hoffman, DE Nichols European journal of pharmacology 132 (2-3), 269-276, 1986 | 377 | 1986 |
| Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor K Kim, T Che, O Panova, JF DiBerto, J Lyu, BE Krumm, D Wacker, ... Cell 182 (6), 1574-1588. e19, 2020 | 365 | 2020 |
| Psychedelics as medicines: an emerging new paradigm DE Nichols, MW Johnson, CD Nichols Clinical Pharmacology & Therapeutics 101 (2), 209-219, 2017 | 363 | 2017 |
| Serotonergic basis of antipsychotic drug effects in schizophrenia JA Lieberman, RB Mailman, G Duncan, L Sikich, M Chakos, DE Nichols, ... Biological psychiatry 44 (11), 1099-1117, 1998 | 309 | 1998 |
| Characterization of three new psychotomimetics T Alexander, DE Nichols The psychopharmacology of hallucinogens, 74-83, 1978 | 293 | 1978 |
| An integrated hypothesis for the serotonergic axonal loss induced by 3, 4-methylenedioxymethamphetamine. JE Sprague, SL Everman, DE Nichols Neurotoxicology 19 (3), 427-441, 1998 | 272 | 1998 |
| Molecular interaction of serotonin 5-HT2A receptor residues Phe339 (6.51) and Phe340 (6.52) with superpotent N-benzyl phenethylamine agonists MR Braden, JC Parrish, JC Naylor, DE Nichols Molecular pharmacology 70 (6), 1956-1964, 2006 | 256 | 2006 |
| trans-10, 11-dihydroxy-5, 6, 6a, 7, 8, 12b-hexahydrobenzo [a] phenanthridine: a highly potent selective dopamine D1 full agonist WK Brewster, DE Nichols, RM Riggs, DM Mottola, TW Lovenberg, ... Journal of medicinal chemistry 33 (6), 1756-1764, 1990 | 248 | 1990 |
| Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes DE Nichols, DH Lloyd, AJ Hoffman, MB Nichols, G Yim Journal of medicinal chemistry 25 (5), 530-535, 1982 | 248 | 1982 |
| Stereochemical effects of 3, 4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H] monoamines into synaptosomes from … TD Steele, DE Nichols, GKW Yim Biochemical pharmacology 36 (14), 2297-2303, 1987 | 242 | 1987 |
| Derivatives of 1-(1, 3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class DE Nichols, AJ Hoffman, RA Oberlender, P Jacob III, AT Shulgin Journal of medicinal chemistry 29 (10), 2009-2015, 1986 | 225 | 1986 |
